JNJ Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

24.14B

+7.18%

2.517

+23.37%

23.05B

+5.29%

2.742

-1%

24.64B

+3.77%

2.858

+3.19%

Estimates Revision

The market is revising Upward the revenue expectations for Johnson & Johnson (JNJ) for FY2025, with the revenue forecasts being adjusted by 0.49% over the past three months. During the same period, the stock price has changed by 9.43%.

Revenue Estimates for FY2025

Revise Upward

+0.49%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.07%

In Past 3 Month

Stock Price

Go Up

+9.43%

In Past 3 Month

20 Analyst Rating

Wall Street analysts forecast JNJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 207.26 USD with a low forecast of 176.00 USD and a high forecast of 230.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

7 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

176.00

Averages

207.26

High

230.00

Current: 0.000

Low

176.00

Averages

207.26

High

230.00

Barclays

Equal Weight

maintain

$197 -> $217

2025-12-30

Reason

Barclays

Price Target

$197 -> $217

2025-12-30

maintain

Equal Weight

Reason

Barclays raised the firm's price target on Johnson & Johnson to $217 from $197 and keeps an Equal Weight rating on the shares. The firm's analysis of sales and scrip data through the last week of December points to upside to consensus estimates in Q4 for J&J, driven primarily by Darzalex, Tremfya and Simponi. Barclays increased estimates ahead of the earnings print.

Goldman Sachs

Asad Haider

maintain

$213 -> $240

2025-12-18

Reason

Goldman Sachs

Asad Haider

Price Target

$213 -> $240

2025-12-18

maintain

Reason

Goldman Sachs analyst Asad Haider raised the firm's price target on Johnson & Johnson to $240 from $213 and keeps a Buy rating on the shares.

RBC Capital

Outperform

maintain

$230 -> $240

2025-12-17

Reason

RBC Capital

Price Target

$230 -> $240

2025-12-17

maintain

Outperform

Reason

RBC Capital raised the firm's price target on Johnson & Johnson to $240 from $230 and keeps an Outperform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC notes that JNJ appears poised to be a top-tier grower in MedTech with its strategy around "portfolio shifting" and "focused innovation" to participate in higher-growth end-markets.

BofA

Neutral

maintain

$204 -> $220

2025-12-15

Reason

BofA

Price Target

$204 -> $220

2025-12-15

maintain

Neutral

Reason

BofA raised the firm's price target on Johnson & Johnson to $220 from $204 and keeps a Neutral rating on the shares. The firm, which believes J&J's premium-sector multiple "looks appropriate for its growth plus asset mix," is shifting its valuation basis to its new FY27 EPS estimate.

Morgan Stanley

Equal Weight

maintain

$190 -> $197

2025-12-12

Reason

Morgan Stanley

Price Target

$190 -> $197

2025-12-12

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Johnson & Johnson to $197 from $190 and keeps an Equal Weight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.

RBC Capital

Outperform

maintain

$209 -> $230

2025-12-11

Reason

RBC Capital

Price Target

$209 -> $230

2025-12-11

maintain

Outperform

Reason

RBC Capital raised the firm's price target on Johnson & Johnson to $230 from $209 and keeps an Outperform rating on the shares after hosting an investor visit to the company's headquarters. Among the firm's positive takeaways is that JNJ's core MedTech business is poised to deliver mid-high single digit sales growth against a backdrop of positive healthcare utilization as the company has been focused on portfolio optimization and disciplined R&D spending on innovations, the analyst tells investors in a research note. The company's Immunology business is also on solid footing despite Stelara loss of exclusivity, the firm added.

Valuation Metrics

The current forward P/E ratio for Johnson & Johnson (JNJ.N) is 18.82, compared to its 5-year average forward P/E of 16.17. For a more detailed relative valuation and DCF analysis to assess Johnson & Johnson 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

16.17

Current PE

18.82

Overvalued PE

17.41

Undervalued PE

14.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

13.00

Current EV/EBITDA

15.18

Overvalued EV/EBITDA

13.86

Undervalued EV/EBITDA

12.14

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.50

Current PS

5.16

Overvalued PS

4.84

Undervalued PS

4.16

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

JNJ News & Events

Events Timeline

No data

News

7.0

19:23 PMNewsfilter

Pfizer Faces Over 2,100 Lawsuits as FDA Approves Brain Tumor Warning

4.5

16:34 PMBarron's

The Dow Approaches 50K: What to Expect Next.

9.0

15:03 PMNASDAQ.COM

Johnson & Johnson Seeks FDA De Novo Classification for OTTAVA Surgical Robot

People Also Watch

Frequently Asked Questions

What is Johnson & Johnson (JNJ) stock price today?

The current price of JNJ is 206.71 USD — it has increased 0.94 % in the last trading day.

What is Johnson & Johnson (JNJ)'s business?

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).

What is the price predicton of JNJ Stock?

What is Johnson & Johnson (JNJ)'s revenue for the last quarter?

Johnson & Johnson revenue for the last quarter amounts to 23.99B USD, increased 6.77 % YoY.

What is Johnson & Johnson (JNJ)'s earnings per share (EPS) for the last quarter?

Johnson & Johnson. EPS for the last quarter amounts to 2.12 USD, increased 90.99 % YoY.

What changes have occurred in the market's expectations for Johnson & Johnson (JNJ)'s fundamentals?

How many employees does Johnson & Johnson (JNJ). have?

Johnson & Johnson (JNJ) has 138100 emplpoyees as of January 07 2026.

What is Johnson & Johnson (JNJ) market cap?

Today JNJ has the market capitalization of 493.40B USD.

JNJ

Overview

Forecast

Valuation

Earnings

JNJ

Overview

Forecast

Valuation

Earnings

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

JNJ News & Events

Events Timeline

No data

News

People Also Watch

Frequently Asked Questions

What is Johnson & Johnson (JNJ) stock price today?

What is Johnson & Johnson (JNJ)'s business?

What is the price predicton of JNJ Stock?

What is Johnson & Johnson (JNJ)'s revenue for the last quarter?

What is Johnson & Johnson (JNJ)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Johnson & Johnson (JNJ)'s fundamentals?

How many employees does Johnson & Johnson (JNJ). have?

What is Johnson & Johnson (JNJ) market cap?